Alfacalcidol
Cat. No.：YN470003
CAS No. ：41294-56-8
规格
价格(RMB)
库存
| 产品名称: | Alfacalcidol |
| CAS No.: | 41294-56-8 |
| Chemical Name: | 5-[2E-[(3aS)-1R-[1R,5-dimethylhexyl]octahydro-7aR-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1R,3R-cyclohexanediol |
| Synonyms: | 阿法骨化醇; 1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3 |
| 分子量: | 400.64 |
| 分子式: | C₂₇H₄₄O₂ |
| SMILES: | C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC(C)C)C)CCC/2)[H])O)O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Alfacalcidol (1-hydroxycholecalciferol) 是一种维生素 D3 的衍生物，是非选择性的维生素 D 受体(VDR)活化剂，有潜力用于骨质疏松的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Holick, M.F.Vitamin D deficiencyN. Engl. J. Med.357(3),266-281(2007)
Peterlik, M., Boonen, S., Cross, H.S., et al.Vitamin D and calcium insufficiency-related chronic diseases: An emerging world-wide public health problemInt. J. Environ. Res. Public Health6(10),2585-2607(2009)
Upton, R.A., Knutson, J.C., Bishop, C.W., et al.Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormoneNephrol. Dial. Transplant18,750-758(2003)
Brown, A.J., Dusso, A.S., and Slatopolsky, E.Vitamin D analogues for secondary hyperparathyroidismNephrol. Dial. Transplant.17(Suppl),10-19(2002)
Frazao, J.M., Chesney, R.W., Coburn, J.W., et al.Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patientsNephrol. Dial. Transplant13,68-72(1998)
Ritter, C.S., and Brown, A.J.Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptorJ. Mol. Endocrinol.46(2),63-66(2011)
Nuti, R., Bianchi, G., Brandi, M.L., et al.Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosisRheumatol. Int.26,445-453(2006)
Pereira, R.M.R., de Carvalho, J.F., Paula, A.P., et al.Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosisRev. Bras. Reumatol.52(4),580-593(2012)
Gravellone, L., Rizzo, M.A., Martina, V., et al.Vitamin D receptor activators and clinical outcomes in chronic kidney diseaseInt. J. Nephrol.,419524(2011)
Jorgensen, H.S., Winther, S., Povlsen, J.V., et al.Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: A retrospective single center studyBMC Nephrol.13(1),(2012)
